What changed: Small-cell lung cancer
Every dated change on the records linked to Small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 3
- 2026GuidelineSmall-cell lung cancerGuideline NCCN SCLC v2.2026: Limited stage
Concurrent cisplatin-etoposide with thoracic radiotherapy (45 Gy twice daily or 60-70 Gy once daily), then durvalumab consolidation up to 2 years (ADRIATIC); PCI or MRI surveillance. (NCCN 1 (durvalumab consolidation, category 1), ESMO-MCBS A)
- 2026GuidelineSmall-cell lung cancerGuideline NCCN SCLC v2.2026: Screening and diagnosis
Low-dose CT screening in heavy smokers finds some SCLC but stage shift is limited; diagnosis by bronchoscopic or CT-guided biopsy; staging with PET/CT and brain MRI. (NCCN SCLC guideline, staging workup)
- 2026MilestoneSmall-cell lung cancerPhase 3 readouts pending for I-DXd and tarlatamab maintenance
A milestone in how this cancer is treated.
2025 · 1
December 2024 · 1
2024 · 2
2021 · 1
March 2020 · 1
2020 · 1
2019 · 3
- 2019MilestoneDurvalumabCASPIAN confirms chemo-immunotherapy with durvalumab
A milestone in how this cancer is treated.
- 2019MilestoneSmall-cell lung cancerRovalpituzumab tesirine (first DLL3 ADC) fails
A milestone in how this cancer is treated.
- 2019MilestoneDLL3Rovalpituzumab tesirine (first DLL3 ADC) fails
A milestone in how this cancer is treated.
February 2018 · 1
2018 · 3
- 2018ApprovalDurvalumabDurvalumab approved in US
Unresectable stage III NSCLC after chemoradiation
- 2018MilestoneSmall-cell lung cancerIMpower133: first immunotherapy OS benefit
A milestone in how this cancer is treated.
- 2018MilestoneSmall-cell lung cancerIMpower133: first survival gain in decades with atezolizumab
A milestone in how this cancer is treated.
2017 · 2
- 2017MilestoneSmall-cell lung cancerCONVERT: once-daily 66 Gy not superior to twice-daily 45 Gy
A milestone in how this cancer is treated.
- 2017MilestoneSmall-cell lung cancerJapanese trial: PCI gives no survival benefit in extensive-stage disease with MRI surveillance
A milestone in how this cancer is treated.